Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03974399 · ClinicalTrials.gov registry record · NA

BDNF Levels After Bacopa

A NA study, sponsored by Roskamp Institute.

Completed
Registry status
NA
Development phase
44
Enrollment target

NCT03974399 is a NA study that has completed, run by Roskamp Institute. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03974399, a NA study, has completed, sponsored by Roskamp Institute.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

Brain-derived neurotrophic factor (BDNF) is a well-known neurotrophic factor important for learning, memory, and synaptogenesis. Healthy activities such as exercise are believed to raise BDNF, while stress is associated with lower BDNF. What is not well understood is if there are certain supplements that may raise BDNF over time. Bacopa monnieri is well characterized nutraceutical. Animal and pre-clinical data support multiple beneficial mechanisms, including raising BDNF and increasing synaptogenesis. Additionally, small studies have shown Bacopa enhances cognition and improves mood. We would like to investigate if BDNF level changes in people after starting Bacopa.

Interventions

  • DIETARY_SUPPLEMENT Bacopa Monnieri

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2019-05-30
Est. Completion 2020-06-01
Phase NA

Sponsor

Roskamp Institute

7 total trials

What the Registry Record Tells You About NCT03974399

The ClinicalTrials.gov registry entry for NCT03974399 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roskamp Institute, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Bacopa Monnieri is the first listed.

NCT03974399 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03974399 about?

NCT03974399 is a clinical study titled "BDNF Levels After Bacopa". Brain-derived neurotrophic factor (BDNF) is a well-known neurotrophic factor important for learning, memory, and synaptogenesis. Healthy activities such as exercise are believed to raise BDNF, while stress is associated with lower BDNF. What is not well understood is if there are certain supplements...

What is the current status of trial NCT03974399?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2019-05-30. Estimated completion is 2020-06-01.

What interventions are being tested in trial NCT03974399?

The interventions under investigation include: Bacopa Monnieri (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03974399?

This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.